Please try another search
For the fiscal year ended 31 December 2019, Vectorite Biomedical Inc revenues decreased 87% to NT$26.5M. Net loss increased from NT$30.3M to NT$90.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Equity Investment Gains decrease from NT$63K (income) to NT$12.5M (expense), Amortization in R&D increase from NT$1.5M to NT$9.1M (expense).
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Revenue | 14.32 | 12.22 | 66.57 | 139.76 |
Gross Profit | -0.65 | 3.47 | 41.55 | 117.45 |
Operating Income | -45.12 | -37.45 | -40.8 | -26.91 |
Net Income | -53.15 | -37.12 | -4.52 | -25.8 |
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Assets | 389 | 426.83 | 363.42 | 555.1 |
Total Liabilities | 103.26 | 87.33 | 28.16 | 218.93 |
Total Equity | 285.75 | 339.51 | 335.26 | 336.17 |
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | -62.72 | -28.52 | -85.28 | -49.53 |
Cash From Investing Activities | -18.88 | -3.48 | -40.08 | -9.46 |
Cash From Financing Activities | 117.27 | 103.38 | 4.03 | 0.6 |
Net Change in Cash | 35.33 | 71.62 | -121.57 | -58.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review